J E Cortes

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Clonal evolution in chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:671-84, x. 2004
  2. doi request reprint Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia
    Courtney D DiNardo
    University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 0428, Houston, TX 77030, USA 1 713 794 5783 1 713 745 4612
    Expert Opin Investig Drugs 23:265-72. 2014
  3. pmc Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
    Aziz Nazha
    Haematologica 98:1686-8. 2013
  4. pmc Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
    Jorge E Cortes
    The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:584-91. 2013
  5. doi request reprint A journey searching for a cure for leukemia
    Jorge E Cortes
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    Future Oncol 9:785-7. 2013
  6. doi request reprint Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
    J Cortes
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:350-4. 2013
  7. doi request reprint Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
    Jorge Cortes
    Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 14:354-62. 2013
  8. pmc Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
    Gautam Borthakur
    Departments of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 98:217-21. 2013
  9. pmc Ponatinib in refractory Philadelphia chromosome-positive leukemias
    Jorge E Cortes
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 367:2075-88. 2012
  10. ncbi request reprint Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
    Jorge Cortes
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:2573-80. 2012

Detail Information

Publications134 found, 100 shown here

  1. ncbi request reprint Clonal evolution in chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:671-84, x. 2004
    ..The continued study of these phenomena will help us to understand better the pathogenesis of CML and improve the long-term treatment of patients with CML...
  2. doi request reprint Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia
    Courtney D DiNardo
    University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 0428, Houston, TX 77030, USA 1 713 794 5783 1 713 745 4612
    Expert Opin Investig Drugs 23:265-72. 2014
    ..This orally bioavailable agent has shown promising activity in vitro and in early clinical trials for patients with relapsed/refractory AML...
  3. pmc Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
    Aziz Nazha
    Haematologica 98:1686-8. 2013
    ..Assessing the response at six months of patients with poor response at three months may provide a better predictor for long-term outcome. ..
  4. pmc Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
    Jorge E Cortes
    The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 13:584-91. 2013
    ..In this analysis we evaluated omacetaxine in CML patients with resistance or intolerance to 2 or more tyrosine kinase inhibitors (TKIs)...
  5. doi request reprint A journey searching for a cure for leukemia
    Jorge E Cortes
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    Future Oncol 9:785-7. 2013
    ..Cortes has spoken at, given presentations at, and appeared as a featured guest at or chaired more than 575 international, national, state and local conferences...
  6. doi request reprint Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
    J Cortes
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:350-4. 2013
    ..Subcutaneous omacetaxine may offer clinical benefit to patients with chronic-phase CML with resistance or intolerance to multiple TKI therapies...
  7. doi request reprint Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
    Jorge Cortes
    Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 14:354-62. 2013
    ..Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat...
  8. pmc Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
    Gautam Borthakur
    Departments of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 98:217-21. 2013
    ..We concluded that HUM-195/rGel can be safely administered in a multi-dose cycle to patients with advanced myeloid malignancies and warrants further investigation...
  9. pmc Ponatinib in refractory Philadelphia chromosome-positive leukemias
    Jorge E Cortes
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 367:2075-88. 2012
    ..Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors...
  10. ncbi request reprint Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
    Jorge Cortes
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:2573-80. 2012
    ..Omacetaxine may provide a safe and effective treatment for CML patients with T315I mutation. This study is registered at www.clinicaltrials.gov as NCT00375219...
  11. doi request reprint How I treat newly diagnosed chronic phase CML
    Jorge Cortes
    University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:1390-7. 2012
    ..In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population...
  12. ncbi request reprint Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
    Jorge E Cortes
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    J Clin Oncol 30:3486-92. 2012
    ..The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML)...
  13. pmc Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
    Naveen Pemmaraju
    Department of Leukemia, University of Texas, Anderson Cancer Center, Houston, TX 77230, USA
    Haematologica 97:1029-35. 2012
    ..Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients...
  14. doi request reprint Bosutinib for the treatment of chronic myeloid leukemia in chronic phase
    A Quintas-Cardama
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Drugs Today (Barc) 48:177-88. 2012
    ..We herein summarize the preclinical and clinical experience of bosutinib in CML...
  15. ncbi request reprint Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1295-302. 2007
    ..Lonafarnib can inhibit the proliferation of imatinib-resistant cells and increases imatinib-induced apoptosis in vitro in cells from imatinib-resistant patients...
  16. ncbi request reprint Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
    Jorge Cortes
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3207-13. 2007
    ..These trials were registered at www.clinicaltrials.gov as #CA180006 and #CA180015...
  17. ncbi request reprint Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 106:1306-15. 2006
    ....
  18. ncbi request reprint Overcoming drug resistance in chronic myeloid leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Opin Hematol 13:79-86. 2006
    ..Thus there is a need for developing approaches to overcome and prevent resistance to imatinib...
  19. ncbi request reprint New targeted approaches in chronic myeloid leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:6316-24. 2005
    ..Many of these agents are already showing promising results in the clinic. This manuscript reviews some of these agents, particularly those for which clinical data are already available...
  20. ncbi request reprint Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Jorge Cortes
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3425-32. 2005
    ..To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib...
  21. ncbi request reprint Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
    Jorge Cortes
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:2805-12. 2005
    ..To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS)...
  22. ncbi request reprint Investigational strategies in chronic myelogenous leukemia
    Jorge E Cortes
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:619-39, ix. 2004
    ..The continued understanding of the biology of CML and mechanisms of resistance to imatinib and the ability to develop target-specific therapies should lead to the increased probability of cure for most patients who have CML...
  23. ncbi request reprint Natural history and staging of chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:569-84, viii. 2004
    ..This article describes the natural history of CML and its prognostic factors,with emphasis on changes due to the emergence of imatinib...
  24. ncbi request reprint Phase I study of bortezomib in refractory or relapsed acute leukemias
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3371-6. 2004
    ..The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents...
  25. ncbi request reprint Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2396-402. 2004
    ..Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and > or = Grade 3 myelosuppression is reported in approximately 10% of patients...
  26. ncbi request reprint Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Clin Lymphoma 4:S30-5. 2003
    ..It is very possible that these agents will soon find their way to the ranks of established agents for the management of myeloid malignancies..
  27. ncbi request reprint CMML: a biologically distinct myeloproliferative disease
    Jorge Cortes
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Curr Hematol Rep 2:202-8. 2003
    ..Future studies should consider CMML as a separate entity to promote a better understanding and identify more effective therapy for patients with this disease...
  28. ncbi request reprint Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:2760-6. 2003
    ..c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD)...
  29. ncbi request reprint Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, 77030, USA
    Blood 110:4005-11. 2007
    ..In this study, there was no marked increase in development of T315I...
  30. ncbi request reprint Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia
    Jorge Cortes
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 6:S22-S30. 2008
    ..Emerging CML therapies, some of which have different mechanisms of action from those of tyrosine kinase inhibitors, have shown promising results and could offer an alternative to these patients as monotherapy or in combination...
  31. doi request reprint Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    J Cortes
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 22:2176-83. 2008
    ..Cytopenias were noted in the majority of patients, and were manageable with dose interruptions/reductions. Dasatinib is associated with a promising rate of response in this high-risk population...
  32. doi request reprint Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Cancer 118:418-27. 2012
    ..The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents...
  33. doi request reprint Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
    Jorge E Cortes
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 117:5600-6. 2011
    ..This study is registered at http://www.clinicaltrials.gov as NCT00471497...
  34. doi request reprint Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    J Clin Oncol 29:524-31. 2011
    ..In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today...
  35. doi request reprint Monitoring molecular response in chronic myeloid leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1113-22. 2011
    ..The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described...
  36. doi request reprint Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating fact
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:572-80. 2011
    ..Interferon alpha (IFN α) is efficacious in CML likely due to its immunomodulatory properties, and is synergistic in vitro with imatinib and granulocyte macrophage-colony stimulating factor (GM-CSF)...
  37. doi request reprint Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study
    Jorge Cortes
    MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:4207-13. 2010
    ..This study in adults evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and with allopurinol alone in controlling plasma uric acid...
  38. doi request reprint Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET)
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4991-5000. 2010
    ..Treatment recommendations have been developed for management of patients with chronic myeloid leukemia (CML)...
  39. doi request reprint Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and
    Jorge E Cortes
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:424-30. 2010
    ..To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase...
  40. pmc Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    Jorge E Cortes
    Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:392-7. 2010
    ..Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant...
  41. pmc Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    Jorge E Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:398-404. 2010
    ..Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase...
  42. ncbi request reprint New agents in chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    J Natl Compr Canc Netw 1:501-12. 2003
    ..If this is successful, complete eradication of disease may become a reality for the majority of patients with CML...
  43. doi request reprint High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
    Jorge E Cortes
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4754-9. 2009
    ..Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML)...
  44. ncbi request reprint Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 11:337-45. 2009
    ..Some of these approaches are expected to improve the outcomes of patients with CML...
  45. doi request reprint Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia
    J E Cortes
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 23:1537-44. 2009
    ..However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML...
  46. pmc The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
    Jorge Cortes
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, USA
    Clin Lymphoma Myeloma Leuk 11:421-6. 2011
    ..Patients with less than complete cytogenetic response to second -line therapy or beyond should be considered to have benefit from therapy and the value of this considered in the context of which alternative options are available...
  47. ncbi request reprint Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:3794-800. 2003
    ..The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy...
  48. doi request reprint Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    Jorge E Cortes
    M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:4567-76. 2011
    ..These data suggest bosutinib is effective and tolerable in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. This trial was registered at http://www.clinicaltrials.gov as NCT00261846...
  49. ncbi request reprint Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  50. ncbi request reprint Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia
    J Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 92:2016-22. 2001
    ..In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL...
  51. ncbi request reprint Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
    Jorge Cortes
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 101:4714-6. 2003
    ..Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES...
  52. ncbi request reprint A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  53. ncbi request reprint High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    J Cortes
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 92:7-14. 2001
    ....
  54. ncbi request reprint Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:1492-9. 2002
    ....
  55. ncbi request reprint Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha
    Jorge Cortes
    Department of Leukemia and Bioimmunotherapy, M D Anderson Cancer Center, University of Texas Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:83-6. 2003
    ..In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission...
  56. ncbi request reprint Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
    E H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 98:3575-83. 2001
    ..It is unlikely that, as given here, either FA or TA is, in general, superior to IA, highlighting the need for new treatments...
  57. ncbi request reprint Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Clin Oncol 19:762-71. 2001
    ..To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia...
  58. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
    B S Dabaja
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, Texas 77030, USA
    Leuk Lymphoma 42:329-37. 2001
    ..0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant toxicity and a moderate impact on survival in RS...
  59. ncbi request reprint Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
    E H Estey
    Department of Leukemia, Division of Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 93:2478-84. 1999
    ..We conclude that addition of ATRA +/- G-CSF to FAI had no effect on CR rate, survival, EFS, or EFS in CR in poor prognosis, newly diagnosed AML or high-risk MDS...
  60. pmc A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome
    N Daver
    Department of Leukaemia, The University of Texas MD Anderson Cancer Centre, Houston, TX 77030, USA
    Eur J Cancer Care (Engl) 22:605-11. 2013
    ..Median time between courses was 42 days (35-72 days). In conclusion homoharringtonine might have clinical activity in some patients with MDS...
  61. doi request reprint A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintas-Cardama
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leukemia 22:965-70. 2008
    ..0014) and returned to 50% at the end of the first 28-day cycle (P=0.016). 5-azacitidine is relatively well tolerated and results in induction of global hypomethylation in patients with MF, but results in limited clinical activity...
  62. ncbi request reprint Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
    A M Tsimberidou
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Leukemia 17:1100-3. 2003
    ..The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required...
  63. ncbi request reprint Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
    F J Giles
    Department of Leukemia; University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA
    Leuk Lymphoma 41:309-19. 2001
    ..01). In conclusion, the addition of intensive chemotherapy may improve survival in patients with CML who have not obtained an adequate cytogenetic response on an IFN-alpha-based regimen...
  64. ncbi request reprint Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature
    A Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 85:58-64. 1999
    ..T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias...
  65. ncbi request reprint Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    J Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 36:479-84. 2000
    ..In summary, the CAT regimen is well tolerated and has significant anti-leukemia activity which warrants further investigation...
  66. ncbi request reprint Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid
    E Estey
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 42:309-16. 2001
    ..Nonetheless, the rates and duration of PCR negativity produced by lipoATRA monotherapy suggest that lipoATRA is a superior anti-APL agent than oral ATRA...
  67. ncbi request reprint Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
    E H Estey
    Department of Leukemia Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:2230-5. 1999
    ..Our data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed APL...
  68. ncbi request reprint Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
    H M Kantarjian
    Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:1414-20. 2001
    ..Myelosuppression and infection remain the most significant complications of therapy in CLL...
  69. ncbi request reprint Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:1767-73. 2006
    ..In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial...
  70. ncbi request reprint Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia
    H Gao
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1905-11. 2005
    ..These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor...
  71. ncbi request reprint Antiangiogenic therapy in leukemia
    D A Thomas
    Department of Leukemia, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Acta Haematol 106:190-207. 2001
    ..The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed...
  72. ncbi request reprint Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:2501-7. 2001
    ..The association of treatment response with survival was evaluated by multivariate and landmark analyses...
  73. ncbi request reprint A prognostic score for patients with lower risk myelodysplastic syndrome
    G Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:538-43. 2008
    ..2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention...
  74. ncbi request reprint High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens
    M Beran
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1999-2015. 2001
    ..Because the results of standard regimens have been disappointing, high-dose chemotherapeutic regimens were investigated recently. In the absence of randomized trials, the relative merits of various treatment regimens are unknown...
  75. doi request reprint Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history
    E Jabbour
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Leukemia 24:6-12. 2010
    ..Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history...
  76. ncbi request reprint Central nervous system involvement in adult acute lymphocytic leukemia
    J Cortes
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Hematol Oncol Clin North Am 15:145-62. 2001
    ..More research is needed to define the intensity and duration of treatment and the role of cranial irradiation in the treatment of isolated CNS relapses...
  77. ncbi request reprint Pilot study of low-dose interleukin-11 in patients with bone marrow failure
    R Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:4165-72. 2001
    ..Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 microg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states...
  78. ncbi request reprint Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
    H M Kantarjian
    Departments of Leukemia, Bioimmunotherapy, Biostatistics, and Blood and Bone Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3513-21. 2000
    ....
  79. ncbi request reprint Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
    F Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, Texas 77030 4095, USA
    Invest New Drugs 19:13-20. 2001
    ....
  80. doi request reprint A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
    S Vadhan-Raj
    Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, MD, USA
    Ann Oncol 23:1640-5. 2012
    ..The efficacy of rasburicase, administered daily for 5 days, has been well established. However, the optimal duration of therapy is unknown in adults...
  81. doi request reprint Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies
    A Quintas-Cardama
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:1117-24. 2008
    ..On the basis of these results, ABL1 kinase inhibitors warrant clinical investigation in patients with NUP214-ABL1-positive T-cell malignancies...
  82. doi request reprint Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome
    R Garg
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 23:1297-302. 2009
    ..Grade III/IV toxicities were mainly cytopenias and neutropenic fever. Combination of rATG, cyclosporine and G-CSF is safe and effective as first-line treatment of AA and has significant activity in low-risk MDS...
  83. ncbi request reprint Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
    A M Tsimberidou
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:139-45. 2005
    ..Recombinant interleukin (IL)-11 is a thrombopoietic growth factor. The purpose of this study was to assess the toxicity, safety and efficacy of low-dose recombinant IL-11 in patients with bone marrow failure (BMF)...
  84. doi request reprint Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications
    I I Raad
    Departments of Infection Control, Infectious Diseases and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 24:1873-9. 2013
    ..Granulocyte transfusions (GTXs) have been used successfully as an adjunctive treatment option for invasive infections in some neutropenic patients with underlying hematologic malignancy (HM)...
  85. ncbi request reprint Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    M Beran
    Departments of Leukemia and Molecular Hematology, and Division of Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2819-30. 1999
    ..To evaluate the efficacy and safety of the combination of topotecan and cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML)...
  86. ncbi request reprint The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1
    J Pan
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 21:1395-404. 2007
    ..Our data establish EXEL-0862 as a solid candidate for the targeted treatment of patients with FIP1L1-PDGFR-alpha-positive HES...
  87. doi request reprint Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution
    F P S Santos
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leukemia 23:2275-80. 2009
    ..The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors...
  88. ncbi request reprint Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia
    R V Fleming
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 40:511-20. 2001
    ..AmBisome was better tolerated than ABLC but was associated with mild abnormalities in liver function tests at the end of therapy...
  89. ncbi request reprint Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
    M Talpaz
    Department of Bioimmunotherapy, M. D. Anderson Cancer Center, Houston, TX, USA
    Blood 98:1708-13. 2001
    ..The results show that PEG IFN-alpha-2b is easier to deliver (once weekly), better tolerated, and perhaps more effective than IFN-alpha...
  90. ncbi request reprint Rituximab dose-escalation trial in chronic lymphocytic leukemia
    H Kantarjian
    Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2165-70. 2001
    ..Efficacy of rituximab was also significant in this group of patients...
  91. pmc Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
    Alfonso Quintas-Cardama
    UT Anderson Cancer Center, Department of Leukemia, Unit 428 1515 Holcombe Blvd Houston, TX 77030, USA
    Haematologica 96:918-21. 2011
    ..02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation...
  92. ncbi request reprint BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia
    S M Kornblau
    Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, 77030 4095, USA
    Clin Cancer Res 6:1401-9. 2000
    ....
  93. ncbi request reprint Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance
    F Ravandi
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1964-72. 2001
    ..The influence of these cellular proteins and caspase-3 activity on apoptosis in CML is complex and merits further investigation...
  94. pmc Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Gautam Borthakur
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 96:62-8. 2011
    ..A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  95. ncbi request reprint Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma
    J A Smith
    Division of Pharmacy, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Chromatogr B Biomed Sci Appl 760:247-53. 2001
    ..1 microg/ml, with the lowest limit of quantitation being 0.2 microg/ml. This method is suitable for routine analysis of UCN-01 in human plasma at concentration from 0.2 to 30 microg/ml...
  96. ncbi request reprint EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
    Jingxuan Pan
    The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 109:315-22. 2007
    ..We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KIT-driven malignancies harboring active site mutations...
  97. ncbi request reprint Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  98. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  99. ncbi request reprint Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents
    Yuk Fung Hui
    Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Invest New Drugs 20:49-53. 2002
    ..This phenomenon should be considered when evaluating toxicity from chemotherapy, particularly when using new and investigational agents...
  100. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  101. ncbi request reprint Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1033-41. 2003
    ....